| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C26H31N5O3 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
AZD0156 is a potent, selective, orally active inhibitor of ATM, with an IC50 of 0.58 nM. It suppresses ATM-mediated signaling, blocks activation of the DNA damage checkpoint, interferes with DNA damage repair, and triggers apoptosis in tumor cells[1]. It is supplied as a white to off-white solid (C26H31N5O3, MW 461.56) at 99.83% purity.
Physical & Chemical Properties
| CAS Number | 1821428-35-6 |
|---|---|
| Molecular Formula | C26H31N5O3 |
| Molecular Weight | 461.56 g/mol |
| Purity | 99.83% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | O=C(N1C2CCOCC2)N(C)C3=C1C4=CC(C5=CC=C(OCCCN(C)C)N=C5)=CC=C4N=C3 |
| Target | ATM |
| Signaling Pathway | Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Apoptosis |
| Solubility | In Vitro: DMSO: 20 mg/mL (43.33 mM; Requires sonication and adjust pH to 3 with HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) DMSO: 4 mg/mL (8.67 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 2 years; -20°C, 1 year. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description. Peer-reviewed publications that used this product are listed under References.
[1]. Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 20 mg/mL (43.33 mM) | requires sonication and adjust pH to 3 with HCl; use freshly opened DMSO (absorbed moisture lowers solubility) |
| DMSO | 4 mg/mL (8.67 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 2 years) or -20°C (up to 1 year); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | 0.83 mg/mL (1.80 mM); clear solution; requires sonication |
| How to prepare | Gives a clear solution at 0.83 mg/mL. For 1 mL of working solution: add 100 μL DMSO stock (8.3 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | 0.83 mg/mL (1.80 mM); suspension; requires sonication |
| How to prepare | Gives a suspension at 0.83 mg/mL. The suspension is suitable for oral and intraperitoneal dosing. For 1 mL of working solution: add 100 μL DMSO stock (8.3 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | 0.83 mg/mL (1.80 mM); clear solution; requires sonication |
| How to prepare | Gives a clear solution at 0.83 mg/mL. Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (8.3 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN. Cancer Discov 2020 Nov;10(11):1742-1757. PMID: 32669286
Multiple cancers escape from multiple MAPK pathway inhibitors and use DNA replication stress signaling to tolerate aberrant cell cycles. Sci Signal 2023 Aug;16(796):eade8744. PMID: 37527351
LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations. Mol Cancer Ther 2026 Jul 15:10.1158/1535-7163.MCT-26-0182. PMID: 42456172
Tumor acidosis-induced DNA damage response and tetraploidy enhance sensitivity to ATM and ATR inhibitors. EMBO Rep 2024 Mar;25(3):1469-1489. PMID: 38366255
Combination of PARP inhibitor and temozolomide to suppress chordoma progression. J Mol Med (Berl) 2019 Aug;97(8):1183-1193.
Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment. Cancers (Basel) 2021 Aug 20;13(16):4200. PMID: 34439352
iScience. 2026 Feb 19;29(3).
Atm inhibition decreases lens opacity in a rat model of galactose-induced cataract. PLoS One 2022 Sep 23;17(9):e0274735. PMID: 36149903
Portland State University. 2026.
bioRxiv. 2026 Jun 2.
